Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02230020 · ClinicalTrials.gov registry record
Efficacy of High Flow Therapy in COPD At Home
A clinical trial, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- 8
- Enrollment target
NCT02230020: Clinical Trial study, sponsored by Johns Hopkins University.
NCT02230020 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02230020 was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Preliminary data show that in COPD patients, HFT substantially decreases ventilatory demand during sleep. The central hypothesis of this proposal is that lowering ventilatory demand using nasal high-flow therapy during sleep will elevate lung function, reduce dyspnea on exertion and improve quality of life. Thus, this proposal aims will determine the effects HFT over time on 1) lung function; 2) dyspnea on exertion; and 3) quality of life.
Primary Outcome
Spirometry will be performed before and after each sleep study
Interventions
- DEVICE Nasal High Flow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-08-15 |
| Est. Completion | 2015-12-13 |
Why NCT02230020 stopped before completion
NCT02230020 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Nasal High Flow is the first listed.
NCT02230020 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02230020 about?
NCT02230020 is a clinical study titled "Efficacy of High Flow Therapy in COPD At Home". Preliminary data show that in COPD patients, HFT substantially decreases ventilatory demand during sleep. The central hypothesis of this proposal is that lowering ventilatory demand using nasal high-flow therapy during sleep will elevate lung function, reduce dyspnea on exertion and improve quality ...
What is the current status of trial NCT02230020?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2013-08-15. Estimated completion is 2015-12-13.
What interventions are being tested in trial NCT02230020?
The interventions under investigation include: Nasal High Flow (DEVICE).
Who is sponsoring clinical trial NCT02230020?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI